Lantern Pharma Inc reports results for the quarter ended in December - Earnings Summary

Lantern Pharma

20/03/2023 21:01

* Lantern Pharma Inc  LTRN.OQ  reported a quarterly adjusted
loss
of 31 cents​​ per share for the quarter ended in December. The
mean expectation of two analysts for the quarter was for a loss
of 47 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Lantern Pharma Inc's reported EPS for the quarter was a
loss
of 31 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Lantern Pharma Inc shares had fallen by 21.4% this
quarter.
    * The company reported a quarterly loss of $3.38 million.
    * Wall Street's median 12-month price target for Lantern
Pharma
Inc is $13.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 20 at 09:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.47          -0.31          Beat
 Sep. 30 2022      -0.48          -0.21          Beat
 Jun. 30 2022      -0.52          -0.41          Beat
 Mar. 31 2022      -0.29          -0.38          Missed